TESARO Inc  

(Public, NASDAQ:TSRO)   Watch this stock  
Find more results for Timothy Pearson�
30.65
+0.34 (1.12%)
Real-time:   1:03PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 29.96 - 31.13
52 week 22.15 - 40.99
Open 31.13
Vol / Avg. 195,487.00/379,564.00
Mkt cap 1.11B
P/E     -
Div/yield     -
EPS -4.18
Shares 36.06M
Beta     -
Inst. own 105%
Feb 17, 2015
Q4 2014 TESARO Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 19, 2014
TESARO Inc at Jefferies Global Healthcare Conference - London
Nov 5, 2014
Q3 2014 TESARO Inc Earnings Call
Nov 5, 2014
Q3 2014 TESARO Inc Earnings Release
Sep 9, 2014
TESARO Inc at Morgan Stanley Healthcare Conference
Sep 4, 2014
TESARO Inc at Robert W. Baird & Co. Inc Health Care Conference
Sep 3, 2014
TESARO Inc at Citi Biotech Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -63.25% -70.25%
Return on average equity -95.20% -77.35%
Employees 62 -
CDP Score - -

Address

SUITE 3300, 1000 WINTER STREET
WALTHAM, MA 02451
United States - Map
+1-339-9700900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TESARO, Inc. (TESARO) is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�s marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). TSR-011 is an orally available anaplastic lymphoma kinase (ALK), inhibitor (targeted anti-cancer agent) is in preclinical development.

Officers and directors

David M. Mott Independent Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Mary Lynne Hedley Ph.D. President, Chief Operating Officer, Director
Age: 51
Bio & Compensation  - Reuters
Leon O. Moulder Jr. Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Timothy R. Pearson Chief Financial Officer, Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Lawrence M. Alleva Independent Director
Age: 64
Bio & Compensation  - Reuters
James O. Armitage M.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Earl M. Collier Jr., Esq. Independent Director
Age: 65
Bio & Compensation  - Reuters
Arnold L. Oronsky Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Beth C. Seidenberg M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters